
Mylan launches new dosages of generic of Novartis hypertension drug in US
pharmafile | April 11, 2016 | News story | Manufacturing and Production | Mylan, Novartis, generic, high blood pressure, hypertension
Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor (metoprolol tartrate), making it the only manufacturer to offer the drug in five strengths.
The US Food and Drug Administration had already approved Mylan’s supplemental abbreviated new drug application (ANDA) for the additional dosages, which will now be available at 37.5mg and 75mg, as well as 25mg, 50mg and 100mg. Statistics from IMS Health suggest that the market for the previous three doses constituted approximately $68.9 million across all manufacturers for the 12 months to February 29 2016.
This high blood pressure generic treatment was just one of the 265 ANDAs that Mylan has filed and are currently pending approval from the FDA, which potentially represent $110.3 billion in annual brand sales.
Sean Murray
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Lilly reports positive results from trial of obesity candidate
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, …






